SCHEMBL674398

SCHEMBL674398

CCCC(CCC)C(=O)Nc1ccc(CCC(=O)NO)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 12/20 1.00
HDAC8 Q9BY41 9/20 1.00
HDAC6 Q9UBN7 8/20 1.00
HDAC2 Q92769 8/20 1.00
HDAC4 P56524 7/20 1.00
HDAC3 O15379 6/20 1.00
HDAC7 Q8WUI4 6/20 1.00
HDAC10 Q969S8 6/20 1.00
HDAC11 Q96DB2 6/20 1.00
HDAC9 Q9UKV0 6/20 1.00
HDAC5 Q9UQL6 6/20 1.00
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA7 P43166 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13839419 0.86 HDAC1 (0.75) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL16187628 0.82 HDAC1 (0.70) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL675340 0.81 HDAC1 (1.00) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL13839420 0.80 HDAC1 (0.79) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL675454 0.77 HDAC1 (1.00) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL675355 0.76 CRHBP (0.70) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL674409 0.76 CRHBP (0.70) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL674410 0.76 CRHBP (0.70) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL26080111 0.75 HDAC1 (0.60) HDAC1HDAC8HDAC6HDAC2HDAC4
SCHEMBL20621920 0.74 MEN1 (0.65) HDAC1HDAC8HDAC6HDAC2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115090-B2 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2015-08-25 US disclosed
US-8318808-B2 Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-11-27 US disclosed
US-20110281950-A1 COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS BAIOCCHI ROBERT A (US) 2011-11-17 US disclosed
WO-2011103563-A1 METHODS AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE GROWTH OF MALIGNANT MAST CELLS ARNO THERAPEUTICS, INC (US) 2011-08-25 WO disclosed
US-20090137679-A1 ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-05-28 US disclosed
US-20070225373-A1 Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225373-A1 Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase HDAC1, BAZ2B, HDAC11 HDAC1 1/4885HDAC8 14/4885HDAC6 13/4885
US-20090137679-A1 ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors HDAC1, HDAC9, HDAC3 HDAC1 1/4885HDAC8 9/4885HDAC6 13/4885
US-20110281950-A1 COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS HDAC1, HDAC4, HDAC2 HDAC1 1/4885HDAC8 9/4885HDAC6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.